# A Study to Learn About a Combined COVID-19 and Influenza Shot in Healthy Adults

> **NCT06237049** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 644 (actual)

## Conditions studied

- Influenza, Human
- SARS-CoV-2 Infection
- COVID-19

## Interventions

- **BIOLOGICAL:** BNT162b2 (Omi XBB.1.5)/RIV
- **BIOLOGICAL:** BNT162b2 (Omi XBB.1.5)
- **BIOLOGICAL:** RIV
- **OTHER:** Normal saline placebo

## Key facts

- **NCT ID:** NCT06237049
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-01-31
- **Primary completion:** 2024-09-13
- **Final completion:** 2024-09-13
- **Target enrollment:** 644 (ACTUAL)
- **Last updated:** 2025-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06237049

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06237049, "A Study to Learn About a Combined COVID-19 and Influenza Shot in Healthy Adults". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06237049. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*